-
EP3917533
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3917533
| EP3917533 - METHODS OF TREATING BREAST CANCER WITH TUCATINIB [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 15.09.2023 Database last updated on 13.11.2024 | |
| Former | Request for examination was made Status updated on 05.11.2021 | ||
| Former | The international publication has been made Status updated on 08.08.2020 | ||
| Former | unknown Status updated on 16.03.2020 | Most recent event Tooltip | 21.06.2024 | New entry: Decision on request for further processing | Applicant(s) | For all designated states Seagen Inc. 21823 30th Drive S.E. Bothell, WA 98021 / US | [N/P] |
| Former [2021/49] | For all designated states Seagen Inc. 21823 30th Drive, S.E. Bothell, WA 98021 / US | Inventor(s) | 01 /
WALKER, Luke c/o SEAGEN INC. 21823 30th Drive Southeast Bothell, WA 98021 / US | 02 /
ENDRES, Christopher, J. c/o SEAGEN INC. 21823 30th Drive Southeast Bothell, WA 98021 / US | 03 /
LEE, Anthony, Jaeyong c/o SEAGEN INC. 21823 30th Drive Southeast Bothell, WA 98021 / US | 04 /
SUN, Hao c/o SEAGEN INC. 21823 30th Drive Southeast Bothell, WA 98021 / US | 05 /
TOPLETZ-ERICKSON, Ariel, R. c/o SEAGEN INC. 21823 30th Drive Southeast Bothell, WA 98021 / US | [N/P] |
| Former [2021/49] | 01 /
WALKER, Luke Bothell, WA 98021 / US | ||
| 02 /
ENDRES, Christopher, J. Bothell, WA 98021 / US | |||
| 03 /
LEE, Anthony, Jaeyong Bothell, WA 98021 / US | |||
| 04 /
SUN, Hao Bothell, WA 98021 / US | |||
| 05 /
TOPLETZ-ERICKSON, Ariel, R. Bothell, WA 98021 / US | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2021/49] | Application number, filing date | 20708761.0 | 24.01.2020 | [2021/49] | WO2020US14953 | Priority number, date | US201962797854P | 28.01.2019 Original published format: US 201962797854 P | [2021/49] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020159822 | Date: | 06.08.2020 | Language: | EN | [2020/32] | Type: | A1 Application with search report | No.: | EP3917533 | Date: | 08.12.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.08.2020 takes the place of the publication of the European patent application. | [2021/49] | Search report(s) | International search report - published on: | EP | 06.08.2020 | Classification | IPC: | A61K31/517, A61K31/7068, A61K39/39, A61K45/06, A61P35/00 | [2021/49] | CPC: |
A61K31/517 (EP,IL,KR,US);
A61K31/155 (US);
A61K31/7068 (KR,US);
A61K39/3955 (US);
A61K45/06 (EP,IL,KR);
A61P35/00 (EP,IL,KR);
A61K2300/00 (KR)
(-)
| C-Set: |
A61K31/517, A61K2300/00 (EP);
A61K31/7068, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/49] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON BRUSTKREBS MIT TUCATINIB | [2021/49] | English: | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | [2021/49] | French: | MÉTHODES DE TRAITEMENT DU CANCER DU SEIN AVEC DU TUCATINIB | [2021/49] | Entry into regional phase | 29.07.2021 | National basic fee paid | 29.07.2021 | Designation fee(s) paid | 29.07.2021 | Examination fee paid | Examination procedure | 29.07.2021 | Examination requested [2021/49] | 29.07.2021 | Date on which the examining division has become responsible | 15.03.2022 | Amendment by applicant (claims and/or description) | 15.09.2023 | Despatch of a communication from the examining division (Time limit: M06) | 17.04.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 12.06.2024 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 12.06.2024 | Request for further processing filed | 12.06.2024 | Full payment received (date of receipt of payment) Request granted | 20.06.2024 | Decision despatched | Fees paid | Renewal fee | 27.01.2022 | Renewal fee patent year 03 | 27.01.2023 | Renewal fee patent year 04 | 29.01.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2018201016 (CASCADIAN THERAPEUTICS INC [US]) [X] 1-134 * paragraph [0006] - paragraph [0007] * * paragraph [0027] * * example - * * claim - *; | [X] - MURTHY RASHMI ET AL, "Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, (20180524), vol. 19, no. 7, doi:10.1016/S1470-2045(18)30256-0, ISSN 1470-2045, pages 880 - 888, XP085413824 [X] 1-134 * abstract * * page 881, column r, paragraph 2 - page 883, column r, paragraph 5 * DOI: http://dx.doi.org/10.1016/S1470-2045(18)30256-0 | by applicant | US4235871 | US4501728 | US4837028 | US4902505 | US4957735 | US5004697 | US5019369 | US5055303 | US5188837 | US5254342 | US5268164 | US5271961 | US5413797 | US5506206 | US5514670 | US5534496 | - "Breast Cancer", HENDERSON I C, Clinical Oncology, American Cancer Society, (19950000), pages 198 - 219 | - "GenBank", Database accession no. NP _001289938 | - FOUCQUIER et al., Pharmacol. Res. Perspect., (20150000), vol. 3, no. 3, page e00149 | - CARTER D, "New global survey shows an increasing cancer burden", Am J Nurs., (20140300), vol. 114, no. 3, page 17 | - GRUBER, BMC Cancer, (20130000), vol. 13, page 328 | - LANGER R., Accounts Chem. Res., (19930000), vol. 26, pages 537 - 542 | - JOHNSTON et al., Pharm. Res., (19920000), vol. 9, pages 425 - 434 | - PEC et al., J. Parent. Sci. Tech., (19900000), vol. 44, no. 2, page 58 65 | - IJNTEMA et al., Int. J. Pharm., (19940000), vol. 112, pages 215 - 224 |